# DESCRIPTION

- claim benefit of prior application

## TECHNICAL FIELD

- define technical field

## BACKGROUND

- describe c-Myc role in cancer

## SUMMARY

- introduce chimeric fusion protein
- describe pharmaceutical composition
- outline method of delivering c-Myc inhibitor
- outline alternative method of delivering c-Myc inhibitor
- describe method of manufacturing chimeric fusion protein
- outline method of preventing or treating c-Myc-dependent cancer

## DETAILED DESCRIPTION

- introduce genetically modified Pseudomonas Aeroginosa Exotoxin A
- describe chimeric fusion protein
- motivate c-Myc-dependent cancers treatment
- provide first embodiment of chimeric fusion protein
- provide second embodiment of pharmaceutical composition
- provide third embodiment of method of delivering c-Myc inhibitor
- provide fourth embodiment of method of delivering c-Myc inhibitor
- provide fifth embodiment of method of manufacturing chimeric fusion protein
- provide sixth embodiment of method of preventing or treating c-Myc-dependent cancer
- provide seventh embodiment of chimeric fusion protein for use
- provide eighth embodiment of use of chimeric fusion protein
- describe genetically modified Pseudomonas Aeroginosa Exotoxin A
- motivate translocation across membranes
- describe Domain Ia and biologically active fragments
- describe Domain II and biologically active fragments
- describe fusion of Domain Ia and Domain II
- motivate c-Myc expression in cancer
- define inhibitor
- describe c-Myc inhibitor
- describe fusion of c-Myc inhibitor to tPE
- define peptide, protein, polypeptide, and amino acid sequence

### 1) Alanine (A), Serine (S), Threonine (T);

- provide conservative amino acid substitution table

### 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

- describe non-conservative amino acid substitutions
- list factors affecting protein properties
- define variant amino acid sequences
- explain percentage identity calculation
- describe cell types
- specify mammalian cell sources
- describe treatment administration
- list mammalian cell types
- specify subject types
- describe c-Myc dependent cancer types
- describe synthetic tags
- specify polyhistidine tag length
- describe pharmaceutical composition
- specify administration amounts
- describe dosage regimes
- define treatment
- define treat
- describe fusion protein formulation
- specify pharmaceutical composition components
- describe carrier types
- list dosage forms
- describe administration routes
- specify pharmaceutically acceptable carriers
- describe composition production
- specify sterile injectable forms
- describe orally acceptable dosage forms
- describe topical administration
- specify delivery vehicles
- describe sustained-release systems

## Definitions

- define singular forms
- define amino acid
- define fragment
- define chimeric protein
- define conjugated, linked, fused, and fusion
- define linear sequence and recombinant

## DESCRIPTION OF EMBODIMENTS

- provide preferred features and embodiments

### Materials and Methods

- synthesize and clone gene sequences
- culture and transduce cell lines
- read luciferase and renilla activity
- express proteins in bacteria
- purify proteins
- quantify and quality control proteins
- test protein activity
- test protein uptake and localization
- perform RNAi knockdown
- fractionate cells after treatment
- co-immunoprecipitate proteins
- test cell proliferation
- perform DRAQ7 assay
- perform RT-PCR
- describe experimental conditions
- describe data analysis
- note additional experiments performed

## RESULTS AND DISCUSSION

- develop genetically modified Pseudomonas Aeroginosa Exotoxin A
- fuse tPE to c-Myc inhibitor H1 peptide
- show tPE-H1 negatively regulates genes controlled by c-Myc
- compare efficiency of tPE-H1 to H1 fused to cell penetrating peptides
- establish stable cell line expressing luciferase upon c-Myc promoter E-Box control
- test activity of tPE-H1
- show tPE-H1 reaches nucleus in less than 1 hour
- disrupt c-Myc/Max interaction with tPE-H1
- show dose response of tPE-H1
- compare EC50 of tPE-H1 to other cell targeting peptides
- show effect of tPE-H1 on cell proliferation
- compare sensitivity of different cell lines to tPE-H1
- fuse tPE to Omomyc peptide
- show activity of tPE-Omomyc
- compare EC50 of tPE-Omomyc to tPE-H1
- show effect of tPE-Omomyc on cell proliferation
- compare sensitivity of different cell lines to tPE-Omomyc
- discuss mechanism of tPE-H1 and tPE-Omomyc
- discuss unexpected results of tPE-H1 and tPE-Omomyc
- compare tPE-H1 and tPE-Omomyc to prior art
- discuss in vivo activity of tPE-H1
- summarize results and discuss implications

